Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics
Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics access to the intravascular ultrasound-guided stenting market. EndoSonics has agreed to pay approximately $15.5 million in cash and EndoSonics common stock, in addition to royalties on future product sales. The deal was expected to close July 31.
The Rancho Cordova, CA, firm also announced last month an agreement in principle to partner with Fukuda Denshi, a Japanese medical products company. Fukuda has agreed to make an equity investment and R&D funding totaling $13 million in EndoSonics.
The agreements cut EndoSonics' final ties to Johnson & Johnson's Cordis division, the company's former distributor and therapeutic product partner. EndoSonics decided to terminate its relationship with Cordis when its product orders declined (SCAN 4/29/98).
In other EndoSonics news, the company reported second-quarter 1998 (end-June) net income of $1 million on revenue of $10 million, a 34% increase over the $751,000 net income on revenue of $7.1 million for the previous year's second quarter.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
What a New Meta-Analysis Reveals About CT Diagnosis of COVID-19
June 2nd 2023In a review of patient data from 42 countries, researchers found that standardized typical findings on computed tomography (CT) for COVID-19 had a pooled sensitivity rate of 70 percent and a pooled specificity rate of 90 percent.
Large Study Shows Mixed Results in Comparison of DBT and Digital Mammography
May 31st 2023In a large retrospective study involving over 523,000 digital breast tomosynthesis (DBT) exams and over one million digital mammography (DM) exams, researchers found that DBT was associated with significantly lower recall rates but showed no advantage over DM in the diagnosis of interval or advanced breast cancer.
2 Clarke Drive
Cranbury, NJ 08512